Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Indaptus Therapeutics ( (INDP) ) has shared an update.
On April 17, 2026, Indaptus Therapeutics, Inc. appointed financial executive Tim Ruan and intellectual property expert Dr. Yi Zhang as independent directors, effective April 22, 2026, strengthening the board with capital markets and life sciences IP expertise. Both were designated Class II directors with terms expiring at the 2026 annual meeting, and Ruan joined the Audit Committee as an audit committee financial expert while Zhang joined the Nominating Committee, as the company continues to refresh its staggered board following the March and April 2026 appointments of Junyi Dai and Qinglai Lu as Class III directors.
In connection with their appointments, Indaptus entered into standard independent director and indemnification agreements with Ruan and Zhang, providing a $30,000 annual cash retainer, expense reimbursement, and broad indemnity under Delaware law, with no related-party arrangements or conflicts disclosed. On April 22, 2026, director Matthew McMurdo resigned from the board without any disagreement over operations, policies, or practices, underscoring that the leadership changes reflect a planned board reconstitution rather than a response to internal disputes.
The most recent analyst rating on (INDP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
Spark’s Take on INDP Stock
According to Spark, TipRanks’ AI Analyst, INDP is a Neutral.
The score is primarily weighed down by weak financial performance (no revenue, widening losses, and heavy cash burn with a shrinking equity cushion), which elevates ongoing financing/dilution risk. Technicals are moderately supportive in the near term (price above key short/mid-term averages and positive MACD), but longer-term trend remains challenged versus the 200-day average. Valuation is constrained by unprofitability (negative P/E), while recent corporate actions point to active capital/cost management but also underscore funding pressure.
To see Spark’s full report on INDP stock, click here.
More about Indaptus Therapeutics
Indaptus Therapeutics, Inc. operates in the biotechnology and life sciences sector, focusing on developing innovative therapies and technologies. The company’s governance structure includes a classified board with staggered three-year terms, and its shares are listed on the Nasdaq Stock Market, requiring compliance with its independence and audit standards.
Average Trading Volume: 51,186
Technical Sentiment Signal: Sell
Current Market Cap: $7.94M
Find detailed analytics on INDP stock on TipRanks’ Stock Analysis page.